

Financial Tear Sheet

Corporate Profile

We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.

Stock Performance

XENE (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$4.10
Change (%)	▲ 0.05 (1.23%)
Volume	89,008
52 Week Low	\$3.65
Market Cap	\$73,786,388
Rolling EPS	-1.68
PE Ratio	0
Shares Outstanding	17,996,680

Data as of 06/23/17 4:00 p.m. ET



Recent Press Releases & Upcoming Events

June 2, 2017 - Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference

There are currently no events scheduled.

May 9, 2017 - Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 4, 2017 - Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results and Provide Corporate Update

SEC Filings

Filing Date	Form
06/23/17	4
06/20/17	4
06/19/17	4
06/08/17	4

Corporate Governance

Simon Pimstone, MBChB, Ph.D., FRCPC

Ian Mortimer, MBA, CPA, CMA

Y. Paul Goldberg, MBChB, Ph.D., FRCPC

Robin Sherrington, Ph.D.

Charles Cohen, PhD

James Empfield, Ph.D.

Raymond Winqvist, Ph.D.

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)